Creo Medical Reschedules Capital Markets Day Due to Clinical Priorities

An announcement from Creo Medical ( (GB:CREO) ) is now available.

Creo Medical Group plc has announced the rescheduling of its Capital Markets Day due to a scheduling conflict involving a keynote speaker who is engaged in a significant clinical procedure. This decision underscores the importance of the clinician’s role in Creo’s clinical program and highlights the company’s commitment to patient care. The rescheduling may impact stakeholder engagement and the company’s market communication strategy, with further details to be announced later.

The most recent analyst rating on (GB:CREO) stock is a Hold with a £12.50 price target. To see the full list of analyst forecasts on Creo Medical stock, see the GB:CREO Stock Forecast page.

Spark’s Take on GB:CREO Stock

According to Spark, TipRanks’ AI Analyst, GB:CREO is a Neutral.

Creo Medical’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. The technical analysis provides a mixed outlook with some short-term positive signals, but the valuation remains poor due to negative earnings. The absence of earnings call data and corporate events means these factors do not influence the score.

To see Spark’s full report on GB:CREO stock, click here.

More about Creo Medical

Creo Medical Group plc is a medical device company specializing in the development and commercialization of minimally invasive electrosurgical devices aimed at improving patient outcomes in surgical endoscopy. The company focuses on advanced energy solutions for endoscopy, utilizing its CROMA technology powered by Kamaptive, which integrates multi-modal energy sources for procedures like resection, dissection, coagulation, and ablation.

Average Trading Volume: 626,081

Technical Sentiment Signal: Strong Sell

Current Market Cap: £48.47M

Learn more about CREO stock on TipRanks’ Stock Analysis page.